Clinical Trials

Below is a list of active clinical trials worldwide which involve patients with inherited bleeding disorders. The link from each study title will take you to ClinicalTrials.gov which gives you more information about the trial.
To see a list of trials for a particular bleeding disorder use the drop-down list below to select the condition you're interested in. A new window will open up with a list of trials for this condition only.

Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B Condition:   Haemophilia Interventions:   Diagnostic Test: Thrombophilia screen;   Diagnostic Test: Initiation pathway analysis Sponsor:   Royal Free Hospital NHS Foundation Trust Recruiting

Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding Condition:   Von Willebrand Disease Intervention:   Other: Non interventional study Sponsor:   Nantes University Hospital Recruiting

UK - EHL Outcomes Registry Conditions:   Hemophilia A;   Hemophilia B Intervention:   Sponsor:   Royal Free Hospital NHS Foundation Trust Recruiting

The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders. Condition:   Glanzmann Thrombasthenia Intervention:   Sponsors:   Rockefeller University;   National Heart, Lung, and Blood Institute (NHLBI) Recruiting

Platelet Glycoproteins in Inherited Thrombocytopathy: Association With Aggregation Studies and Bleeding Severity Conditions:   Bleeding;   Platelet Dysfunction Intervention:   Diagnostic Test: Flowcytometry analysis of platelets surface receptors Sponsor:   Assiut University Recruiting

A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People and Patients With Bleeding Disorder Conditions:   Healthy Volunteers;   Haemophilia A With or Without Inhibitors Interventions:   Drug: NNC0365-3769 A (Mim8);   Drug: Placebo (Mim8) Sponsor:   Novo Nordisk A/S Not yet recruiting

REAL-LIFE DATA OF CONSTITUTIONAL VON WILLEBRAND DISEASE IN WESTERN FRANCE (HOPSCOTcH-WILL) Condition:   Von Willebrand Diseases Intervention:   Other: VWD treatments Sponsors:   Nantes University Hospital;   CHU de Brest;   University Hospital, Angers;   CH Le Mans;   Rennes University Hospital Not yet recruiting

Real World Study of Deep Venous Thrombosis. Analysis of Prospective Cases in University Hospitals of São Paulo Condition:   Registry Intervention:   Other: deep venous thrombosis Sponsors:   Fundação Faculdade Regional de Medicina de São José do Rio Preto;   University of Ribeirao Preto Recruiting

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia Condition:   Hereditary Hemorrhagic Telangiectasia Intervention:   Sponsors:   St. Michael's Hospital, Toronto;   National Institute of Neurological Disorders and Stroke (NINDS) Recruiting

Evaluation of Patients With Immune Function Abnormalities Conditions:   Immune System Diseases;   Chronic Granulomatous Disease (CGD);   X-Linked Severe Combined Immune Deficiency (XSCID);   Leukocyte Adhesion Deficiency 1 (LAD);   Graft Versus Host Disease (cGvHD) Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting

Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease. Condition:   Hereditary Hemorrhagic Telangiectasia Interventions:   Other: Phase 1 : fill out 1 scale;   Other: Phase 2 : fill out 1 scale and 4 questionnaires Sponsor:   Hospices Civils de Lyon Not yet recruiting

BAX 111 rVWF in Pediatrics Condition:   Von Willebrand Disease Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant) Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire Recruiting

Investigation of the Genetics of Hematologic Diseases Conditions:   Bone Marrow Failure Syndromes;   Erythrocyte Disorder;   Leukocyte Disorder;   Hemostasis;   Blood Coagulation Disorder;   Sickle Cell Disease;   Dyskeratosis Congenita;   Diamond-Blackfan Anemia;   Congenital Thrombocytopenia;   Severe Congenital Neutropenia;   Fanconi Anemia Intervention:   Sponsors:   St. Jude Children's Research Hospital;   Boston Children’s Hospital;   Baylor College of Medicine;   University of Memphis Recruiting

World Bleeding Disorders Registry Conditions:   Hemophilia A;   Hemophilia B Intervention:   Sponsor:   World Federation of Hemophilia Not yet recruiting

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients Conditions:   Hereditary Hemorrhagic Telangiectasia;   Osler Weber Rendu Disease Interventions:   Drug: Propranolol treatment;   Drug: Placebo Sponsors:   University Hospital, Bordeaux;   AMRO-HHT-France - Association Maladie de Rendu-Osler Not yet recruiting

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery Condition:   Factor 10 Deficiency Intervention:   Drug: Coagadex Sponsor:   Bio Products Laboratory Recruiting

Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors Conditions:   Adeno-Associated Virus (AAV);   Blood Coagulation Disorder;   Blood Coagulation Disorders, Inherited;   Coagulation Protein Disorders;   Factor VIII (FVIII);   Factor VIII (FVIII) Deficiency;   Factor VIII (FVIII) Gene;   Factor VIII (FVIII) Protein;   Genetic Diseases, Inborn;   Genetic Diseases, X-Linked;   Gene Therapy;   Gene Transfer;   Hematologic Diseases;   Hemorrhagic Disorders;   Recombinant;   Vector;   Inhibitors Intervention:   Genetic: SPK-8016 Sponsor:   Spark Therapeutics Recruiting

Doxycycline for Hereditary Hemorrhagic Telangiectasia Condition:   Hereditary Hemorrhagic Telangiectasia (HHT) Interventions:   Drug: Doxycycline Hyclate;   Drug: Placebo Sponsors:   St. Michael's Hospital, Toronto;   Barrow Neurological Institute;   Duke University;   Feinstein Institute for Medical Research;   University of Pittsburgh;   Sunnybrook Health Sciences Centre Recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors Conditions:   Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Hemophilia A Intervention:   Drug: Emicizumab Sponsor:   Hoffmann-La Roche Recruiting

Swiss Hemophilia Registry Condition:   Hemophilia and Other Severe Bleeding Disorders Intervention:   Other: Registry Sponsor:   Swiss Hemophilia Network Recruiting

Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT) Condition:   Hereditary Hemorrhagic Telangiectasia Interventions:   Biological: Blood samples;   Other: Epistaxis charts Sponsor:   Centre Hospitalier Universitaire Dijon Recruiting

Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia Conditions:   Hereditary Hemorrhagic Telangiectasia;   Epistaxis Nosebleed;   Anemia Interventions:   Drug: Pazopanib;   Drug: Placebo oral capsule Sponsor:   Cure HHT Not yet recruiting

Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia Condition:   Hereditary Hemorrhagic Telangiectasia Interventions:   Drug: Timolol Gel;   Drug: Placebo Gel Sponsor:   Washington University School of Medicine Recruiting

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants Conditions:   Blood Coagulation Disorder;   Blood Coagulation Disorders, Inherited;   Coagulation Protein Disorders;   Hemophilia A;   Genetic Diseases, Inborn;   Genetic Diseases, X-Linked;   Hematologic Diseases;   Hemorrhagic Disorders;   Factor VIII Deficiency Intervention:   Drug: Standard of Care FVIII Replacement therapy Sponsor:   Spark Therapeutics Recruiting

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) Conditions:   Thrombotic Thrombocytopenic Purpura;   Congenital Thrombotic Thrombocytopenic Purpura;   Familial Thrombotic Thrombocytopenic Purpura;   Thrombotic Thrombocytopenic Purpura, Congenital;   Upshaw-Schulman Syndrome Intervention:   Other: Observation Sponsors:   University Hospital Inselspital, Berne;   Swiss National Science Foundation;   Mach Gaensslen Foundation;   Baxalta Innovations GmbH, Wien, Austria Recruiting

Vitamin D and Hereditary Haemorrhagic Telangiectasia Condition:   Hereditary Haemorrhagic Telangiectasia Interventions:   Drug: Vit D;   Drug: Placebo Oral Tablet Sponsor:   St. Paul's Hospital, Canada Recruiting

Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families Condition:   Telangiectasia, Hereditary Hemorrhagic Intervention:   Sponsors:   Imperial College London;   British Heart Foundation Recruiting

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study Conditions:   Hereditary Hemorrhagic Telangiectasia;   Idiopathic Vascular Ectasia Intervention:   Drug: Pomalidomide Sponsor:   The Cleveland Clinic Recruiting

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia Conditions:   Hereditary Hemorrhagic Telangiectasia;   Epistaxis Intervention:   Drug: Pazopanib Sponsors:   Cure HHT;   University of North Carolina Not yet recruiting

Pregnancy and Fibrinogen Disorders Conditions:   Hypofibrinogenemia, Congenital;   Afibrinogenemia, Congenital;   Dysfibrinogenemia, Congenital Intervention:   Sponsors:   University Hospital, Geneva;   Swiss Hemophilia Network Recruiting

Pomalidomide for the Treatment of Bleeding in HHT Condition:   Telangiectasia, Hereditary Hemorrhagic Interventions:   Drug: Pomalidomide Oral Product;   Drug: Placebo oral capsule Sponsors:   The Cleveland Clinic;   RTI International Recruiting

Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry Conditions:   Hereditary Hemorrhagic Telangiectasia;   HHT;   Brain Arteriovenous Malformation (BAVM) Intervention:   Other: Registry and Saliva sample Sponsors:   St. Michael's Hospital, Toronto;   HHT Foundation International;   Dartmouth College Recruiting

Evaluation of Video-assisted Instructions of Nasal Self-packing in Patients With HHT Condition:   Hereditary Haemorrhagic Telangiectasia Intervention:   Procedure: video-assisted nasal self-packing Sponsor:   University Hospital, Essen Recruiting

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment Conditions:   Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Haemophilia A Intervention:   Drug: Standard of Care for Haemophilia A Sponsor:   Hoffmann-La Roche Recruiting

Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT) Conditions:   Hereditary Hemorrhagic Telangiectasia (HHT);   Epistaxis Interventions:   Drug: Floseal;   Other: Packing Sponsors:   St. Michael's Hospital, Toronto;   The Ottawa Hospital Recruiting

Modifiers of Disease Severity in Cerebral Cavernous Malformations Conditions:   Cavernous Angioma, Familial;   Cerebral Cavernous Malformations;   Cerebral Cavernous Hemangioma Intervention:   Sponsors:   University of California, San Francisco;   University of New Mexico;   University of Chicago;   National Institute of Neurological Disorders and Stroke (NINDS);   Boston Children’s Hospital;   Children's Hospital Medical Center, Cincinnati;   Barrow Neurological Institute;   Angioma Alliance Recruiting

A Gene Transfer Study for Hemophilia A Condition:   Hemophilia A Intervention:   Genetic: SPK-8011 Sponsor:   Spark Therapeutics Recruiting

Low VW Activity in Adolescent HMB Condition:   Von Willebrand Factor Deficiency Interventions:   Other: Genetic Analysis;   Other: Medical Record Data Abstraction;   Other: Pictorial Blood Assessment Chart (PBAC) score;   Other: Complete Bleeding Symptom ISTH Bleeding Assessment Tool Sponsors:   Baylor College of Medicine;   Shire Recruiting

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B Conditions:   Congenital Bleeding Disorder;   Haemophilia B Intervention:   Drug: nonacog beta pegol Sponsor:   Novo Nordisk A/S Recruiting

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A Condition:   Severe Hemophilia A Intervention:   Drug: OCTA101 Sponsor:   Octapharma Recruiting

Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany Conditions:   Hereditary Hemorrhagic Telangiectasia;   Dental Diseases Intervention:   Sponsors:   University Hospital, Essen;   Philipps University Marburg Medical Center;   University Hospital, Aachen;   German HHT self-help group Recruiting

Handheld Ultrasound (HHUS) for Home Use in Hemophilia Conditions:   Joint Bleed;   Hemophilia A Intervention:   Device: handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform Sponsors:   Bloodworks;   Genentech, Inc. Not yet recruiting

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors Conditions:   Hemophilia A;   Hemophilia B Interventions:   Drug: fitusiran;   Drug: factor VIII or factor IX Sponsor:   Genzyme, a Sanofi Company Recruiting

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors Conditions:   Hemophilia A;   Hemophilia B Interventions:   Drug: fitusiran;   Drug: recombinant Factor VIIa and FEIBA Sponsor:   Genzyme, a Sanofi Company Recruiting

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab Condition:   Hemophilia A With Inhibitor Intervention:   Drug: Feiba Sponsors:   Children's Hospital Los Angeles;   Takeda Not yet recruiting

Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia Condition:   Thrombocytopenia Intervention:   Drug: Eltrombopag Sponsors:   University Hospital, Toulouse;   French network for inherited hemorragic diseases;   National Reference Centre for Platelet Pathologies Recruiting

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A Condition:   Hemophilia A Intervention:   Other: assessment of joint health and bone density Sponsors:   Bloodworks;   Genentech, Inc. Recruiting

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency Condition:   Factor VII Deficiency Interventions:   Biological: Eptacog alfa, biosimilar and reference medicinal product Novoseven;   Biological: Eptacog alfa biosimilar Sponsor:   AryoGen Pharmed Co. Recruiting

Ultrasonography in Hemophilic Joint Disease and Serum Markers Conditions:   Hemophilia A;   Hemophilia B;   Hemarthroses Intervention:   Other: ultrasound Sponsors:   Northwell Health;   National Cancer Institute (NCI);   University of California, San Diego Recruiting

Von Willebrand Disease in the Netherlands Condition:   Von Willebrand Disease Intervention:   Sponsors:   Erasmus Medical Center;   Stichting Haemophilia (Dutch Haemophilia Foundation);   CSL Behring;   Shire Not yet recruiting

Longitudinal Studies of Patient With FPDMM Conditions:   Inherited Hematological Diseases;   Rare Diseases;   FPDMM Intervention:   Sponsor:   National Human Genome Research Institute (NHGRI) Recruiting

Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome Condition:   Hermansky-Pudlak Syndrome (HPS) Intervention:   Sponsor:   National Human Genome Research Institute (NHGRI) Recruiting

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Conditions:   Adrenoleukodystrophy;   Batten Disease;   Mucopolysaccharidosis II;   Leukodystrophy, Globoid Cell;   Leukodystrophy, Metachromatic;   Neimann Pick Disease;   Pelizaeus-Merzbacher Disease;   Sandhoff Disease;   Tay-Sachs Disease;   Brain Diseases, Metabolic, Inborn;   Alpha-Mannosidosis;   Sanfilippo Mucopolysaccharidoses Intervention:   Biological: DUOC-01 Sponsors:   Joanne Kurtzberg, MD;   The Marcus Foundation Recruiting

A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt Conditions:   Hemophilia;   Von Willebrand Diseases;   Christmas Disease Intervention:   Sponsor:   Safaa AA Khaled Not yet recruiting

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors Condition:   Hemophilia Intervention:   Sponsor:   Karolinska Institutet Recruiting

A Factor IX Gene Therapy Study (FIX-GT) Condition:   Hemophilia B Intervention:   Biological: FLT180a Sponsor:   University College, London Recruiting

A Study of Haemophilia B Patients Who Have Undergone Gene Therapy Condition:   Hemophilia B Intervention:   Biological: FLT180a Sponsor:   Freeline Therapeutics Recruiting

TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia Condition:   Haemophilia A Intervention:   Other: Thrombin generation measurement. Sponsor:   Hospices Civils de Lyon Recruiting

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation) Condition:   Hemophilia A Intervention:   Drug: Damoctocog alfa pegol (Jivi, BAY94-9027) Sponsor:   Bayer Recruiting

ATHN 2: Factor Switching Study Condition:   Hemophilia Interventions:   Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013;   Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 Sponsors:   American Thrombosis and Hemostasis Network;   Shire;   CSL Behring;   Bioverativ Therapeutics Inc.;   Bayer Recruiting

Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease Condition:   Type 1 Von Willebrand Disease Interventions:   Drug: recombinant von Willebrand factor;   Drug: tranexamic acid Sponsors:   Margaret Ragni;   University of North Carolina;   Duke University Recruiting

Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis Conditions:   Pulmonary Fibrosis;   Healthy Volunteers;   Hermansky-Pudlak Syndrome (HPS) Intervention:   Sponsor:   National Human Genome Research Institute (NHGRI) Recruiting

Intranasal Bevacizumab for HHT-Related Epistaxis Conditions:   HHT;   Hereditary Hemorrhagic Telangiectasia;   Epistaxis;   Nose Bleeds;   Nasal Bleeding Interventions:   Drug: Bevacizumab;   Drug: Placebo (Saline) Sponsor:   Stanford University Recruiting

A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13) Condition:   Congenital Thrombotic Thrombocytopenic Purpura Interventions:   Biological: BAX930;   Biological: Standard of care Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire Recruiting

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions Conditions:   All Diagnosed Health Conditions;   ADD/ADHD;   Alopecia Areata;   Ankylosing Spondylitis;   Asthma;   Atopic Dermatitis Eczema;   Beta Thalassemia;   Bipolar Disorder;   Breast Cancer;   Celiac Disease;   Cervical Cancer;   Chronic Inflammatory Demyelinating Polyneuropathy;   Chronic Kidney Diseases;   Chronic Obstructive Pulmonary Disease;   Colon Cancer;   Colorectal Cancer;   Crohn's Disease;   Cystic Fibrosis;   Depression;   Diabetes Mellitus;   Duchenne Muscular Dystrophy;   Endometriosis;   Epilepsy;   Facioscapulohumeral Muscular Dystrophy;   G6PD Deficiency;   General Anxiety Disorder;   Hepatitis B;   Hereditary Hemorrhagic Telangiectasia;   HIV/AIDS;   Human Papilloma Virus;   Huntington's Disease;   Idiopathic Thrombocytopenic Purpura;   Insomnia;   Kidney Cancer;   Leukemia;   Lung Cancer;   Lupus Nephritis;   Lymphoma;   Melanoma;   Multiple Myeloma;   Multiple Sclerosis;   Myositis;   Myotonic Dystrophy;   Ovarian Cancer;   Pancreatic Cancer;   Parkinson's Disease;   Polycystic Kidney Diseases;   Prostate Cancer;   Psoriasis;   Psoriatic Arthritis;   Rosacea;   Scleroderma;   Sickle Cell Anemia;   Sickle Cell Trait;   Sjogren's Syndrome;   Skin Cancer;   Spinal Muscular Atrophy;   Systemic Lupus Erythematosus;   Thrombotic Thrombocytopenic Purpura;   Trisomy 21;   Ulcerative Colitis Intervention:   Sponsor:   Sanguine Biosciences Recruiting

Study of Chediak-Higashi Syndrome Condition:   Chediak Higashi Syndrome Intervention:   Sponsor:   National Human Genome Research Institute (NHGRI) Recruiting

Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases Conditions:   Von Willebrand Diseases;   Glanzmann Thrombasthenia Interventions:   Device: Sublingual videomicroscopy;   Biological: blood sample Sponsor:   University Hospital, Lille Not yet recruiting

An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B Condition:   Hemophilia B Intervention:   Drug: Alprolix Sponsor:   Swedish Orphan Biovitrum Recruiting

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B Conditions:   Haemophilia A;   Haemophilia B Interventions:   Drug: ELOCTA;   Drug: ALPROLIX Sponsor:   Swedish Orphan Biovitrum Recruiting

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment Condition:   Von Willebrand Diseases Intervention:   Drug: VWF-containing products Sponsor:   Octapharma Recruiting

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry Condition:   Hemophilia A Intervention:   Drug: New FVIII products Sponsors:   Bayer;   American Thrombosis and Hemostasis Network Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program Recruiting

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis Condition:   Hemophilia A, Congenital Intervention:   Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973 Sponsor:   Bayer Recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A Condition:   Hemophilia A Intervention:   Drug: Damoctocog alfa pegol (Jivi, Bay94-9027) Sponsor:   Bayer Recruiting

ATHN 7: Hemophilia Natural History Study Conditions:   Hemophilia A With Inhibitor;   Haemophilia A Without Inhibitor;   Hemophilia B With Inhibitor;   Haemophilia B Without Inhibitor Intervention:   Sponsors:   American Thrombosis and Hemostasis Network;   Genentech, Inc. Recruiting

rVWF IN PROPHYLAXIS Condition:   Von Willebrand Disease Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant) Sponsor:   Baxalta now part of Shire Recruiting

China Registry for Genetic / Metabolic Liver Diseases Condition:   Genetic/Metabolic Liver Diseases Intervention:   Drug: Standard of care Sponsors:   Beijing Friendship Hospital;   Beijing YouAn Hospital;   Henan Provincial Hospital;   Beijing Ditan Hospital;   Hebei Medical University Third Hospital;   Peking University First Hospital;   Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital;   Nanfang Hospital of Southern Medical University;   Logistics University of Chinese People's Armed Police Forces;   Beijing Anzhen Hospital;   West China Second University Hospital of Sichuan University;   Jinshan Hospital of Fudan University;   Fudan University Recruiting

Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B Conditions:   Haemophilia A;   Haemophilia B Intervention:   Sponsor:   Swedish Orphan Biovitrum Recruiting

Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients Condition:   Von Willebrand Diseases Intervention:   Sponsor:   University Hospital, Lille Recruiting

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B Conditions:   Hemophilia A;   Hemophilia B Intervention:   Drug: PF-06741086 Sponsor:   Pfizer Recruiting

ATHN 8: PUPs Matter Study Conditions:   Hemophilia;   Hemophilia A;   Hemophilia B;   Hemophilia A With Inhibitor;   Hemophilia B With Inhibitor;   Haemophilia B Without Inhibitor;   Haemophilia A Without Inhibitor;   Haemophilia Intervention:   Sponsors:   American Thrombosis and Hemostasis Network;   CSL Behring;   Octapharma;   Takeda Recruiting

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients Condition:   Hemophilia B Intervention:   Genetic: AAV5-hFIXco-Padua Sponsor:   UniQure Biopharma B.V. Recruiting

rVWF Pediatric and Adult Study Condition:   Von Willebrand Disease Interventions:   Biological: rVWF;   Biological: rFVIII Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire Recruiting

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD Condition:   Von Willebrand Diseases Intervention:   Drug: Wilate Sponsor:   Octapharma Not yet recruiting

Effectiveness and Tolerability of Eqwilate in Real-life Conditions Condition:   VWD - Von Willebrand's Disease Intervention:   Biological: Eqwilate Sponsor:   Octapharma Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors Condition:   Hemophilia A Interventions:   Biological: Nuwiq;   Biological: Octanate;   Biological: Wilate;   Biological: Emicizumab;   Biological: Recombinant factor VIIa (rFVIIa);   Biological: Activated prothrombin complex concentrate (aPCC) Sponsors:   Emory University;   Octapharma Not yet recruiting

Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients Conditions:   Thrombocytopenia;   Splenectomy Intervention:   Procedure: splenectomy Sponsor:   Zhang Lei Recruiting

Evaluation of Bleeding Score in Egyptian Patients With vWD Type I and Correlate it With Laboratory Parameters Condition:   Von Willebrand Disease, Type 1 Intervention:   Diagnostic Test: The von Willebrand Antigen level Sponsor:   Assiut University Not yet recruiting

Differences in Preparation for Small Bowel Capsule Endoscopy Conditions:   Capsule Endoscopy;   Inflammatory Bowel Diseases;   Celiac Disease Interventions:   Drug: Klean Prep;   Other: Clear liquids only Sponsors:   Sheffield Teaching Hospitals NHS Foundation Trust;   Hotel Dieu Hospital Recruiting

Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease Conditions:   Inflammatory Bowel Diseases;   Von Willebrand Diseases Intervention:   Diagnostic Test: von willebrand antigen and activity Sponsor:   Assiut University Recruiting

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) Condition:   Hemophilia A Interventions:   Biological: ADVATE;   Biological: ADYNOVI Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire Recruiting

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Condition:   Hemophilia B Intervention:   Biological: rIX-FP Sponsor:   CSL Behring Recruiting

The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B Condition:   Hemophilia Interventions:   Other: Blood sample;   Other: Questionnaire;   Other: MRI-imaging;   Other: Physical examination Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Recruiting

Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions Conditions:   Von Willebrand Diseases;   Major Constitutional Thrombopathy;   Patient on Antiplatelet Drugs Intervention:   Biological: Blood sampling Sponsor:   Centre Hospitalier Universitaire Dijon Recruiting

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab Condition:   Acquired Hemophilia A Interventions:   Drug: Steroid;   Drug: Rituximab;   Drug: Cyclophosphamide Sponsors:   Zhang Lei;   Qilu Hospital of Shandong University;   Tianjin First Central Hospital;   The Second Affiliated Hospital of Kunming Medical University;   Henan Cancer Hospital Recruiting

Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype Condition:   Hemophilia B Intervention:   Other: data collection Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting

The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B) Conditions:   Hemophilia A;   Hemophilia B Interventions:   Drug: SerpinPC;   Drug: Placebo Sponsor:   ApcinteX Ltd Recruiting

Clinical Performance Evaluation of T-TAS 01 PL Chip Conditions:   Platelet Dysfunction;   Von Willebrand Diseases;   Healthy;   Congenital Platelets Abnormality Interventions:   Diagnostic Test: T-TAS 01 PL Chip;   Diagnostic Test: PFA-100 Col/Epi and Col/ADP Sponsors:   Hikari Dx, Inc.;   Fujimori Kogyo Co., Ltd. Recruiting

Von Willebrand Factor Concentrate During ECMO Support Condition:   Acquired Von Willebrand Disease Interventions:   Drug: Von Willebrand Factor;   Drug: Saline Solution Sponsors:   Tirol Kiniken GmbH;   LFB BIOMEDICAMENTS Recruiting

Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. Condition:   Hemophilia A Intervention:   Drug: Recombinant Human Coagulation FVIII Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting

Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia Condition:   Haemophilia Intervention:   Other: EHL clotting factor Sponsor:   Investigación en Hemofilia y Fisioterapia Not yet recruiting

Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study) Condition:   Hemophilia A Intervention:   Drug: Damoctocog alfa pegol (Jivi, BAY94-9027) Sponsor:   Bayer Not yet recruiting

A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1) Condition:   Factor VIII Deficiency Intervention:   Drug: BIVV001 Sponsor:   Sanofi Recruiting

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis Condition:   Hemophilia Intervention:   Drug: Fitusiran Sponsor:   Genzyme, a Sanofi Company Recruiting

Update in VWD Laboratory Diagnosis Condition:   VWD - Von Willebrand's Disease Intervention:   Sponsor:   Assiut University Not yet recruiting

Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A. Condition:   Hemophilia A Intervention:   Drug: Recombinant Human Coagulation FVIII Sponsor:   Sinocelltech Ltd. Not yet recruiting

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency Conditions:   Congenital Afibrinogenemia;   Congenital Hypofibrinogenemia Intervention:   Biological: BT524 (fibrinogen concentrate from human plasma) Sponsors:   Biotest;   ICON plc;   SYNLAB Analytics & Services Germany GmbH;   Phoenix Clinical Research;   Accovion GmbH Recruiting